source
- Biopharma chases new immunology targets as Humira and Dupixent set high barJohnson & Johnson, Pfizer, Argenx and several other companies are expanding their immunology pipelines, seeking new targets and improvements to capture part of the market driven by AbbVie’s Humira…
- FDA proposes new BsUFA IV commitment letter to streamline biosimilar reviewsThe U.S. Food and Drug Administration released a draft commitment letter for the Biosimilar User Fee Act (BsUFA IV) program, highlighting several departures from the existing biosimilar review fram…